Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
0.5360
+0.0650 (13.80%)
At close: Aug 3, 2026, 4:00 PM EDT
0.5400
+0.0040 (0.75%)
Pre-market: Aug 4, 2026, 6:48 AM EDT
Evogene Revenue
Evogene had revenue of $334.00K in the quarter ending March 31, 2026, a decrease of -85.74%. This brings the company's revenue in the last twelve months to $1.84M, down -70.41% year-over-year. In the year 2025, Evogene had annual revenue of $3.85M, down -30.91%.
Revenue (ttm)
$1.84M
Revenue Growth
-70.41%
P/S Ratio
2.69
Revenue / Employee
$35,462
Employees
52
Market Cap
4.96M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.85M | -1.72M | -30.91% |
| Dec 31, 2024 | 5.58M | 2.60M | 87.02% |
| Dec 31, 2023 | 2.98M | 1.31M | 78.03% |
| Dec 31, 2022 | 1.68M | 745.00K | 80.11% |
| Dec 31, 2021 | 930.00K | -110.00K | -10.58% |
| Dec 31, 2020 | 1.04M | 287.00K | 38.11% |
| Dec 31, 2019 | 753.00K | -994.00K | -56.90% |
| Dec 31, 2018 | 1.75M | -1.63M | -48.33% |
| Dec 31, 2017 | 3.38M | -3.16M | -48.30% |
| Dec 31, 2016 | 6.54M | -4.59M | -41.23% |
| Dec 31, 2015 | 11.13M | -3.38M | -23.31% |
| Dec 31, 2014 | 14.51M | -3.07M | -17.46% |
| Dec 31, 2013 | 17.58M | 509.00K | 2.98% |
| Dec 31, 2012 | 17.07M | 2.17M | 14.57% |
| Dec 31, 2011 | 14.90M | 2.34M | 18.61% |
| Dec 31, 2010 | 12.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioAtla | 2.00M |
| Bio Green Med Solution | 1.53M |
| GeoVax Labs | 852.28K |
| CollPlant Biotechnologies | 389.00K |
| BioRestorative Therapies | 357.87K |
| AIM ImmunoTech | 94.00K |
| Soligenix | 2.34K |
EVGN News
- 5 days ago - Evogene Schedules Second Quarter 2026 Financial Results Release - PRNewsWire
- 12 days ago - Evogene (EVGN) Partners with ELEO for PCSK9 Inhibitor Development - GuruFocus
- 12 days ago - Evogene and ELEO announce scientific collaboration - TheFly
- 12 days ago - Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases - PRNewsWire
- 19 days ago - AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities - PRNewsWire
- 26 days ago - Evogene (EVGN) Partners with Tel Aviv University for Drug Discovery Innovation - GuruFocus
- 27 days ago - Evogene, BCDD announces strategic joint initiative - TheFly
- 27 days ago - Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery - PRNewsWire